75 related articles for article (PubMed ID: 38481529)
1. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).
Schindeler A; Little DG
Bone; 2008 Apr; 42(4):616-22. PubMed ID: 18248783
[TBL] [Abstract][Full Text] [Related]
2. Pluripotent Stem Cells to Model Degenerative Retinal Diseases: The RPE Perspective.
Dalvi S; Galloway CA; Singh R
Adv Exp Med Biol; 2019; 1186():1-31. PubMed ID: 31654384
[TBL] [Abstract][Full Text] [Related]
3. Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.
Darle A; Mahiet T; Aubin D; Doyen M; El Kassar L; Parfait B; Lemaitre G; Baldeschi C; Allouche J; Holic N
Front Cell Dev Biol; 2024; 12():1359561. PubMed ID: 38481529
[TBL] [Abstract][Full Text] [Related]
4. Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides.
Dong Y; Peng T; Wu W; Tan D; Liu X; Xie D
J Int Med Res; 2019 Apr; 47(4):1717-1730. PubMed ID: 30819013
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.
Kuhrt LD; Motta E; Elmadany N; Weidling H; Fritsche-Guenther R; Efe IE; Cobb O; Chatterjee J; Boggs LG; Schnauß M; Diecke S; Semtner M; Anastasaki C; Gutmann DH; Kettenmann H
Dis Model Mech; 2023 Dec; 16(12):. PubMed ID: 37990867
[TBL] [Abstract][Full Text] [Related]
6. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
[TBL] [Abstract][Full Text] [Related]
7. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
8. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
9. Efficient Differentiation of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Mesenchymal Progenitors Into Adipocytes and Osteoblasts.
Diaz-Hernandez ME; Khan NM; Drissi H
Bio Protoc; 2023 Nov; 13(22):e4885. PubMed ID: 38023794
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
11. The Promises and Pitfalls of CRISPR-Mediated Base Editing in Stem Cells.
Wong PK; Mohamad Zamberi NN; Syafruddin SE; Cheah FC; Azmi N; Law JX; Chua EW
CRISPR J; 2023 Jun; 6(3):196-215. PubMed ID: 37219623
[TBL] [Abstract][Full Text] [Related]
12. Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems.
Silva-Pedrosa R; Salgado AJ; Ferreira PE
Cells; 2023 Mar; 12(6):. PubMed ID: 36980271
[TBL] [Abstract][Full Text] [Related]
13. Molecular Dissection of Somatic Skeletal Disease in Neurofibromatosis Type 1.
Paria N; Khalid A; Shen B; Lemoine B; Chan J; Kidane YH; Oxendine I; Cornelia R; Wise CA; Rios JJ
J Bone Miner Res; 2023 Feb; 38(2):288-299. PubMed ID: 36459048
[TBL] [Abstract][Full Text] [Related]
14. Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques.
Ahmed R; Uppuganti S; Derasari S; Meyer J; Pennings JS; Elefteriou F; Nyman JS
J Bone Miner Res; 2022 Aug; 37(8):1603-1621. PubMed ID: 35690920
[TBL] [Abstract][Full Text] [Related]
15. Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.
Ferrara UP; Tortora C; Rosano C; Assunto A; Rossi A; Pagano S; Falco M; Simeoli C; Ferrigno R; D'Amico A; Di Salvio D; Cangemi G; Pivonello R; Strisciuglio P; Melis D
Sci Rep; 2022 Mar; 12(1):4368. PubMed ID: 35288591
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
